Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2013 | 12-2012 | 12-2011 | 12-2006 | |
| Sales | 617 | 717 | 557 | 0 |
| Cost of Goods | N/A | N/A | 5 | N/A |
| Gross Profit | 617 | 717 | 552 | N/A |
| Operating Expenses | 38,842 | 43,903 | 28,295 | 0 |
| Operating Income | -38,225 | -43,186 | -27,738 | N/A |
| Interest Expense | 15,164 | 28,959 | 17,790 | 0 |
| Other Income | 941 | 13,886 | 665 | 0 |
| Pre-tax Income | -52,448 | -58,259 | -44,863 | 0 |
| Net Income Continuous | -52,448 | -58,259 | -44,863 | N/A |
| Net Income | $-52,448 | $-58,259 | $-44,863 | $N/A |
| EPS Basic Total Ops | 1.17 | -290.48 | -226.06 | N/A |
| EPS Basic Continuous Ops | -238.16 | -290.48 | -226.06 | N/A |
| EPS Diluted Total Ops | 1.05 | -290.48 | -226.06 | N/A |
| EPS Diluted Continuous Ops | -50.96 | -290.48 | -226.06 | N/A |
| EBITDA(a) | $-31,999 | $-33,682 | $-20,621 | $N/A |